Spyre Therapeutics, Inc. SYRE Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one?
- Spyre Therapeutics, Inc. (SYRE) reported debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one of $419.2M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one changed year-over-year?
- Spyre Therapeutics, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one increased by 14.2% year-over-year, from $367.11M to $419.2M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one has grown at a 176.5% compound annual growth rate (CAGR), from $20.85M to $440.9M.